がん関連血栓症の予防のための成人参加者におけるREGN7508 (ROXI-CAT-I)
固形腫瘍の癌治療を受けている参加者における癌関連血栓症の一次予防のための、FXIに対するモノクローナル抗体REGN7508の有効性と安全性を評価する第3相、多施設共同、無作為化、二重盲検、プラセボ対照試験(ROXI-CAT-I)
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Clinical Trials Administrator
- 電話番号:844-734-6643
- メール:clinicaltrials@regeneron.com
研究場所
-
-
Florida
-
Hialeah、Florida、アメリカ、33013
- 募集
- Bioresearch Partner- Hialeah Hospital
-
North Miami Beach、Florida、アメリカ、33169
- 募集
- Helios Clinical Research
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Beth Israel Deaconess Medical Center
-
-
New York
-
New York、New York、アメリカ、10021
- 募集
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
El Paso、Texas、アメリカ、79902
- 引きこもった
- El Paso Medical Research Institute (Medresearch Inc)
-
-
-
-
-
Tbilisi、グルジア、0159
- 募集
- Institute of Clinical Oncology
-
Tbilisi、グルジア、0186
- 募集
- Caucasus Medical Centre
-
Tbilisi、グルジア、0144
- 募集
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
Tbilisi、グルジア、0179
- 募集
- LTD Cancer Research Centre
-
Tbilisi、グルジア、0179
- 募集
- JSC Evex Hospitals - Caraps Medline
-
Tbilisi、グルジア、0102
- 募集
- American Hospital Tbilisi
-
Tbilisi、グルジア、0112
- 募集
- Llc Todua Clinic
-
Tbilisi、グルジア、0112
- 募集
- Israel Georgia Medical Research Clinic Helsicore
-
-
Adjara
-
Batumi、Adjara、グルジア、6000
- 募集
- LTD High Technology Hospital Medcenter
-
-
Imereti
-
Kutaisi、Imereti、グルジア、4600
- 募集
- Krystyna Kiel Oncology Center
-
-
-
-
-
Niigata、日本、951-8520
- 募集
- Niigata University Medical & Dental Hospital
-
-
Ehime
-
Tōon、Ehime、日本、791-0295
- 募集
- Ehime University Hospital
-
-
Gunma
-
Ōta、Gunma、日本、373-8550
- 募集
- Gunma Prefectural Cancer Center
-
-
Hyōgo
-
Akashi、Hyōgo、日本、673-8558
- 募集
- Hyogo Cancer Center
-
-
Kagawa-ken
-
Kita-gun、Kagawa-ken、日本、761-0793
- 募集
- Kagawa University Hospital
-
-
Kanagawa
-
Isehara-Shi、Kanagawa、日本、259-1193
- 募集
- Tokai University Hospital
-
-
Kyoto
-
Kyoto、Kyoto、日本、602-8566
- 募集
- University Hospital Kyoto Prefectural University of Medicine
-
-
Miyagi
-
Sendai、Miyagi、日本、980-8574
- 募集
- Tohoku University Hospital
-
-
Osaka
-
Chuo、Osaka、日本、540-0006
- 募集
- National Hospital Organization Osaka National Hospital (ONH)
-
-
Saitama
-
Ina-machi、Saitama、日本、362-0806
- 募集
- Saitama Cancer Center
-
-
Tokyo
-
Chuo Ku、Tokyo、日本、104-0045
- 募集
- National Cancer Center Hospital - Tsukiji Campus
-
Shinjuku、Tokyo、日本、160-0023
- 募集
- Tokyo Medical University Hospital
-
-
Yamaguchi
-
Ube、Yamaguchi、日本、755-8505
- 募集
- Yamaguchi University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
- Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
Key Exclusion Criteria:
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
- Has a primary brain tumor or brain metastases as described in the protocol
- Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:プラセボ
|
Administered per the protocol |
|
実験的:REGN7508
|
Administered per the protocol
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
中央判定による国際血栓止血学会(ISTH)主要出血または臨床的関連性のある非主要(CRNM)出血の初回イベント発現までの時間
時間枠:6ヶ月間を通じて
|
6ヶ月間を通じて
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
時間枠:Through 6 months
|
Through 6 months
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
治療関連有害事象(TEAE)の発生
時間枠:245日目まで
|
245日目まで
|
|
TEAEの重症度
時間枠:最大245日目まで
|
最大245日目まで
|
|
REGN7508に対するADAの大きさ
時間枠:最大245日目まで
|
最大245日目まで
|
|
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic VTE
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic DVT
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic non-fatal PE
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of thromboembolism-related death
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental VTE
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE-related death
時間枠:Through 6 months
|
Through 6 months
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
時間枠:Through 6 months
|
Through 6 months
|
|
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
時間枠:Up to day 245
|
Up to day 245
|
協力者と研究者
捜査官
- スタディディレクター:Clinical Trial Management、Regeneron Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- R7508-CAT-2392
- 2024-519298-21-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD 共有時間枠
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共有アクセス基準
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。